Blood filtering shows promise for chronic fatigue sufferers

NCT ID NCT07529197

Recruiting now Disease control Sponsor: Charite University, Berlin, Germany Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at a blood-filtering procedure called immunoadsorption (IA) in 50 people with ME/CFS or Post-COVID syndrome who have certain autoantibodies. The goal is to see if removing these antibodies improves symptoms like severe fatigue and brain fog. Researchers will track changes in physical function and daily work ability over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Immunoadsorption (IA) using TheraSorb® column
What this could lead to: If successful, this could point toward a treatment for ME/CFS and Post-COVID syndrome by removing harmful antibodies from the blood.
What could go wrong: This is an early observational study with only 50 participants, so results may not apply to everyone. The procedure is not a cure and may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ME/CFS FOLLOWING COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myalgic encephalomeyelitis/chronic fatigue syndrome post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ME/CFS FOLLOWING COVID-19 MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS)

Contacts and locations

Locations

Charité - Universitätsmedizin Berlin
RECRUITING

Berlin, State of Berlin, 10117, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.